chrisvoncsefalvay/vaers-outcomes huggingface dataset:
stomach pain/ severe stomach pain; Sick; headache; feeling tired; diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL PAIN UPPER (stomach pain/ severe stomach pain), ILLNESS (Sick), DIARRHOEA (diarrhea), HEADACHE (headache) and FATIGUE (feeling tired) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 16-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In December 2021, the patient experienced DIARRHOEA (diarrhea). On 16-Dec-2021, the patient experienced ABDOMINAL PAIN UPPER (stomach pain/ severe stomach pain), ILLNESS (Sick), HEADACHE (headache) and FATIGUE (feeling tired). At the time of the report, ABDOMINAL PAIN UPPER (stomach pain/ severe stomach pain), ILLNESS (Sick), HEADACHE (headache) and FATIGUE (feeling tired) had not resolved and DIARRHOEA (diarrhea) outcome was unknown.            Patient had her 1st and 2nd doses of the Moderna COVID-19 vaccine in Apr2021 and was not sure if that was the 1st or 2nd dose.   No relevant concomitant medications was reported. Treatment information was not reported.   Most recent FOLLOW-UP information incorporated above includes: On 22-Dec-2021: Follow-up received includes Event added diarrhea.
got back to back Flu after influenza vaccine last 2 years; Initial information regarding an unsolicited valid non-serious case received from a consumer (patient) via social media on 07-Nov-2020.  This case involves a patient of an unknown demographics who had got back to back flu (influenza), while patient received Influenza vaccine last 2 years.  The patient's medical history, past medical treatment(s), vaccination(s) and family history were not provided. Past vaccination included a dose of INFLUENZA VACCINE and patient got flu.  Concomitant medication was not reported.   On an unspecified date in 2019, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer, lot number not reported) via an unknown route at an unknown administration site prophylactic vaccine.  On an unspecified date in 2019, the patient got flu (influenza), unknown latency following the administration of INFLUENZA VACCINE.  It was reported that patient got back to back flu after influenza vaccine last 2 years and not long after getting the flu shot. Hence the patient did not go for the flu shot present year.  Lab details were not reported.  It was not reported if the patient received a corrective treatment.  At the time of reporting, outcome of the event was not reported.  There will be no information regarding the batch number of the case.
This spontaneous report as received from a nurse refers to a multiple unspecified patients of unknown age and gender. On an unknown date, the patients were vaccinated with improperly stored doses of RECOMBIVAX HB (dose and route of administration were not reported, lot # J014855 with expiration date: 16-APR-2016 and K010216 with expiration date: 12-MAY-2016). No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 01-AUG0-2016, the patient was vaccinated with an improperly stored dose of GARDASIL 0.5 ml (lot # K011492, expiration date 31-JAN-2017). No adverse effects were reported. This specified lot number vaccine was exposed to temperature excursion three times. The total cumulative excursion time (hour), the lowest recorded temperature (Fahrenheit degree/Celsius) and the type of excursion (R/F) for each time were 24, 34 and R. The total cumulative excursion time (hour), the highest recorded temperature (Fahrenheit degree/Celsius) and the type of excursion (R/F) for each time were 176, 48 and R; 48, 47 and R.. The storage criteria was refrigerator (R). This is one of several reports received from the same source. Additional information has been requested
Patient was clammy, getting tunnel vision, and hearing was "tightening". Blood pressure was 101/56. this happened roughly 5 minutes after administration
Eight days after the initial vaccination, I developed COVID rash at the injection site and on my face.  It cleared at the injection site, but not on my face.  I also had a headache and nausea for the first 7 days (no fever).  Because of the severity of the reaction to the first injection, I checked with my PCP and rheumatologist before the second injection.  Labs were run that only showed an elevated white blood cell count.  They encouraged me to proceed with the second vaccination.  The hives surged after that and eventually I was unable to manage them with anti-histamines.  I am now on Xolair and anti-histamines, in an effort to manage the hives.
3AM morning of 11JUN93 woke mom w/t104.2, sl wheezing, h/a, stomach upset-no vomiting; has been on APAP & using cool compresses; lowest temp 103.4 @ 830AM;
Information has been received from a consumer concerning a 32 year old female patient with chronic fatigue syndrome and depression who on an unknown dates was vaccinated with the first and second dose of GARDASIL at a health department. Concomitant therapy included "anti-candida herbal remedy" [therapy unspecified]. The consumer reported that the patient on 01-AUG-2008 and 14-AUG-2008 said that she was hallucinating, seeing double, had blurry vision and heard voices". The consumer reported that the patient said that she "had these symptoms for 4 months which rendered her incapable to take care of her son". Additional information was not available.
Overnight was seen to have 2 episodes with legs shaking and eyes looking up. Second time Mom noticed was very warm with fever. Only other time he had seizure was after MMR and VARIVAX given 4/7/10 and had seizure-febrile 4/12/10. (Fine by AM).
Information has been received from a pharmacist referring to 2 patients of unknown age and gender. The patients' medical history, concurrent condition and concomitant therapy were not reported. On unknown dates, each of the patients was vaccinated with a dose of improperly stored ZOSTAVAX (lot # M033335, expiration date 11-OCT-2017, dose and route not reported) for prophylaxis. The doses of vaccine were improperly stored at 8.96 degree Fahrenheit for 2 hours. There was no previous temperature excursion. Data logger was involved. No adverse effects were reported. Additional information has been requested.
Soreness at site RSQ, no symptoms noted, then noted in mirror "hives" at injection site, warm to touch and itchy, and redness which went away week of 11/16/07. Approx 11/14 symptoms of Rt shoulder pain with ROM and touch began. Has treated with moist heat, anti-inflammatories, Tylenol, changed bras and different bed pillows - no relief. Has some noted swelling of Rt axilla. No redness, tenderness or swelling at injection site.
Headache; TIRED/a bit tired; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache) and FATIGUE (TIRED/a bit tired) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product PANCREATIN (CREON) for Ulcerative colitis.    No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form On an unknown date, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. and PANCREATIN (CREON) (Oral) at an unspecified dose. On an unknown date, the patient experienced HEADACHE (Headache) and FATIGUE (TIRED/a bit tired). At the time of the report, HEADACHE (Headache) and FATIGUE (TIRED/a bit tired) outcome was unknown.            No concomitant medication was reported. On an unknown date, patient received first, second and booster dose of COVID-19 vaccine manufactured by Moderna. The patient had a mild headache and was a bit tired after the second dose. For the booster dose, patient had mild body aches and was extremely tired for 12 hours and then energy recovered. The onset happened 12 to 16 hours after the shot. It was unknown if patient was enrolled in a COVID-19 vaccine trial. No treatment medication was reported.  Primary reporter declined to be contacted.  Causality for CREON(PANCREATIN): The reporter's causality for the event(s) of HEADACHE and TIRED was not provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   This case was linked to MOD-2021-624853.
Nose bleed; Chills; Body aches; Fever; This spontaneous case was reported by a nurse and describes the occurrence of EPISTAXIS (Nose bleed), CHILLS (Chills), MYALGIA (Body aches) and PYREXIA (Fever) in a 23-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011D21A and 004C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 26-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Aug-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Aug-2021, the patient experienced CHILLS (Chills), MYALGIA (Body aches) and PYREXIA (Fever). On 24-Aug-2021, the patient experienced EPISTAXIS (Nose bleed). At the time of the report, EPISTAXIS (Nose bleed) had resolved and CHILLS (Chills), MYALGIA (Body aches) and PYREXIA (Fever) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The concomitant medication were not reported.   No treatment medication were reported by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 24-Aug-2021: FU received on 24-AUG-2021 contains No new information
Fever up to 103.2 even with fever reducers, red swollen injection site, soreness of leg, fussiness, tiredness, poor appetite, dizziness, weakness, falling over, slight lethargy, restless sleeping. All symptoms resolved within 48 hours except the swelling and redness of the injection limb are still there.
This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a adult female patient who received SHINGRIX for prophylaxis. On 24th December 2018, the patient received the 1st dose of SHINGRIX. On 24th December 2018, 2 hrs after receiving SHINGRIX, the patient experienced pain in arm, chills, nausea, headache and fatigue. On 25th December 2018, the outcome of the pain in arm, chills, nausea, headache and fatigue were recovered/resolved. It was unknown if the reporter considered the pain in arm, chills, nausea, headache and fatigue to be related to SHINGRIX. Additional details were reported as follows: The age at vaccination was not reported. The patient experienced a sore arm about 2 hours afterwards. Later that evening of vaccination, after about 7 hours after the dose, the patient experienced chills, nausea, fatigue and headache. The reporter did not give consent to follow up.
underneath her breast a big red spot like an iron burn but not itchy; red spot at injection site; pain arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (pain arm), RASH MACULAR (underneath her breast a big red spot like an iron burn but not itchy) and VACCINATION SITE ERYTHEMA (red spot at injection site) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Mar-2021, the patient experienced PAIN IN EXTREMITY (pain arm) and VACCINATION SITE ERYTHEMA (red spot at injection site). On 28-Mar-2021, the patient experienced RASH MACULAR (underneath her breast a big red spot like an iron burn but not itchy). At the time of the report, PAIN IN EXTREMITY (pain arm), RASH MACULAR (underneath her breast a big red spot like an iron burn but not itchy) and VACCINATION SITE ERYTHEMA (red spot at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment information included hydrocortisone cream, Benadryl no concomitant drugs included
After my Third Covid-19 booster injection I got mild pain in my left shoulder and arm (injection arm). Consult doctor, advised me it normal and go away in couple of day or month. Later after my fourth booster the pain got worse and now it seem frozen shoulder. Got advise from doctor and gave me shot in shoulder and taking pain medication and physiotherapy. Symptom did not subside, cannot move my arm above shoulder, cannot sleep well. Next appointment with doctor is coming and advise to get MRI.
This spontaneous report was received from a registered nurse regarding an unspecified patient of unknown demographics. There was no information about concurrent condition and historical medication. On an unknown date in August 2014, the patient was vaccinated with GARDASIL dose 1 and dose 2 on 25-AUG-2015 (inappropriate schedule of drug administration) (dose, strength, route and lot number was unknown). No concomitant medication was reported. No adverse event was reported. No product quality complaint (PQC) was involved. The outcome of the event was unknown. Additional information has been requested.
I started 48 hours after receving the first dose, it started with some pain in my left feet, and from then the pain went through all the leg, the next day the same effect but in the right leg, continuing the pain in the  left leg, also a lot of pain in aboth arms, and fingers. Pain increase a lot in the night, mostly muscular pain, but also like circulatory pain. One day I woke up and I have a pain in one finger of my right hand, as if I broke the finger, pain in the finger dissapear through the day. Also one night I have an extreme pain in both arms.
I've had a 50-cent piece sized red area and lump and pain when I lay on it at night.; I've had a 50-cent piece sized red area and lump and pain when I lay on it at night.; I've had a 50-cent piece sized red area and lump and pain when I lay on it at night.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 58-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 19Apr2022 at 11:45 as dose 4 (booster), single (Lot number: FJ4989) at the age of 58 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "mild IBS" (unspecified if ongoing), notes: mild IBS; "Known Allergies:penicillin" (unspecified if ongoing); "Known Allergies:latex" (unspecified if ongoing); "Known Allergies:sulfa" (unspecified if ongoing), notes: Known Allergies:sulfa; "Known Allergies:shellfish" (unspecified if ongoing); "Known Allergies:tomatoes" (unspecified if ongoing), notes: Known Allergies:tomatoes. Concomitant medication(s) included: METOPROLOL; ASPIRIN [ACETYLSALICYLIC ACID]. Vaccination history included: Bnt162b2 (Dose: 1), for Covid-19 Immunization, reaction(s): "a little sore"; Bnt162b2 (Dose: 2), for Covid-19 Immunization, reaction(s): "a little sore"; Bnt162b2 (Dose: 3), for Covid-19 Immunization, reaction(s): "a little sore". The following information was reported: VACCINATION SITE ERYTHEMA (non-serious), VACCINATION SITE MASS (non-serious), VACCINATION SITE PAIN (non-serious) all with onset 20Apr2022 at 07:00, outcome "not recovered" and all described as "I've had a 50-cent piece sized red area and lump and pain when I lay on it at night.". Therapeutic measures were taken as a result of vaccination site erythema, vaccination site mass, vaccination site pain.  Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. List of other medications the patient received within 2 weeks of vaccination: Metoprolol, Low dose Aspirin, Vitamins. The 1st three Pfizer COVID19 vaccines did not do anything to arm, except a little sore. This last dose was imperceptible the first day, but the next 3 days, She has had a 50-cent piece sized red area and lump and pain when she lay on it at night. She put an ice pack on it. Prior to vaccination, the patient was diagnosed with COVID-19 and since the vaccination, the patient not has been tested for COVID-19. Device Date mentioned as 21Apr2022.  No follow-up attempts are possible. No further information is expected.
This spontaneous report as received from a licensed practical nurse refers to a patient of unknown age and unknown gender. The patient pertinent medical history was not reported. On 25-NOV-2014, the patient was vaccinated with ZOSTAVAX (dose strength and route was not reported) (lot # K01104 and expiry date: 07-NOV-2015) which was improperly stored. Primary reporter was reporting excursion of 6 F since 10-JUN-2013 (confirmed date) affecting ZOSTAVAX, nurse also reported that products were not stored in an overall average support range of -58 degree F and 5 degree F. No adverse effects reported. No product quality complaint (PQC) was reported ZOSTAVAX. This is one of the several reports from the same reporter. Additional information has been requested.
I started getting symptoms of shortness of breath. I tested on the March 15th which was negative and again on March 16th which was positive. On March 17th, I also had a PCR test that was positive. I had fever, and developed swelling in knees and ankles with general aches and pains. I quarantines for 10 days and went back to work and felt bad again. I went back to the doctor due to cough and was put on prednisone, albuterol, amoxicillin. I still have symptoms now.
No adverse event; 113 Bivalent doses administered after the BUD to patients 12 and up.; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (113 Bivalent doses administered after the BUD to patients 12 and up.) and NO ADVERSE EVENT (No adverse event) in a 57-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7148B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 08-Dec-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. On 08-Dec-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (113 Bivalent doses administered after the BUD to patients 12 and up.). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (113 Bivalent doses administered after the BUD to patients 12 and up.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (113 Bivalent doses administered after the BUD to patients 12 and up.).    Concomitant medication was not provided. Treatment medication information was not provided by the reporter. It was reported that breakdown of doses is as follows- 51 doses from Lot AS7140C, and 60 doses from Lot AS7148B.
Developed a rash on his arms and hands after getting the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Developed a rash on his arms and hands after getting the vaccine) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced RASH (Developed a rash on his arms and hands after getting the vaccine). At the time of the report, RASH (Developed a rash on his arms and hands after getting the vaccine) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication details were reported.  It was reported that the patient still had some areas of the rash that have not gone away. No treatment medication details were reported.
3/8/11 Given first influenza vaccination. 3/17/11 Experienced stomach pain and nausea; took Peptobismal without relief. 3/18/11 at 1115 AM Reported to work with complaints of: stomach upset, loss of appetite; chills. Sent home to recover. Follow-up with physician/care clinic. 3/23/11 Seen at Urgent Care Clinic. Prescribed PRILOSEC. 3/24/11 Presented to hospital ED for evaluation. Hospitalized 2 days. Given IV fluids and PRILOSEC. Released from hospital 3/26/11. Continues on PRILOSEC - slow steady recovery. Diagnosed with pancreatitis during hospitalization.
devel gen varicella rash involving trunk, face, extremities (25-50 pox) & fever;
After the first two doses of Pfizer Covid vaccines I suffered significant increase in tinnitus.  I took a hearing test that confirmed an increase in tinnitus but no particular hearing loss.   After the booster dose there was a hearing loss in the right ear and fullness in the ear that was not resolving.  I visited an urgent care facility and then an ENT where I was started on oral prednisone treatment and administered hearing tests that confirmed sudden hearing loss.  Treatment is continuing with little benefit.  An MRI confirmed that there was no Acoustic Neuroma causing the loss of hearing.  First two doses were taken at the local health department clinics and the final one was taken at a local pharmacy. The dates of the first two injections were 2/11/2021 and 3/4/2021.  The first hearing test was on 4/29/2021.  The date of booster shot was 10/5/2021.
My first dose was Pfizer and my second dose was Moderna; This spontaneous case was reported by an other health care professional and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (My first dose was Pfizer and my second dose was Moderna) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: pfizer. Past adverse reactions to the above products included No adverse event with pfizer.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (My first dose was Pfizer and my second dose was Moderna). At the time of the report, INTERCHANGE OF VACCINE PRODUCTS (My first dose was Pfizer and my second dose was Moderna) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant treatment was provided. No treatment medication was provided.
Weakness, shortness of breath, itchy throat, cough, poor range of motion in shoulder where vaccin administered. Symptoms bad for 3 days 24h after vaccination and lingered for 3 weeks.
Three hours after injection, pt. c/o fever of 104.8, weakness, shaky, joints ached, chills.  States "her legs buckled and I couldn't walk". She stated "her joints locked up and she was shaking,like I was having a convulsion".  Threw up once, stated "breathing hurt".  Fever continued for approximately 2-3 days, at around 102 degrees.